Evidence for dopaminergic and serotonergic regulation of prolactin cell activity in the trout Salmo gairdneri.
The control of prolactin (PRL) cell activity in Salmo gairdneri was investigated in vivo and in vitro. In some in vivo experiments treatment was followed by estimation of pituitary PRL content by gel electrophoresis or of PRL cell nuclear area by light microscopy. In the remainder, treatment was followed by incubation of the pituitary glands in drug-free medium for estimation of PRL synthesis and release. The dopamine precursor, L-dopa (20 mg/kg), reduced pituitary PRL content. Conversely, the dopamine-receptor blocker, domperidone (10 mg/kg), increased total PRL content and amount released in the subsequent incubation. The initial serotonin precursor, L-tryptophan (75 mg/kg), increased pituitary PRL content and PRL cell nuclear area. 5-HTP (20 mg/kg), the immediate serotonin precursor, increased both percentage PRL release and total PRL levels during subsequent incubation. Pargyline (25 mg/kg) treatment to inhibit serotonin catabolism elevated PRL levels in pituitary and medium during subsequent incubation. The serotonin synthesis blocker, parachlorophenylalanine (pCPA; 100 mg/kg), nonsignificantly reduced PRL cell nuclear area. When this was followed by incubation, percentage PRL release and total PRL fell significantly. During in vitro incubation, dopamine (2 micrograms/ml) reduced the release of PRL into the medium, while serotonin (10(-5) M) increased PRL release. These results suggest that both an inhibitory dopaminergic and a stimulatory serotonergic system may be involved in PRL cell regulation in S. gairdneri. The lack of any significant effect of cortisol (1 microgram/ml), somatostatin (300 ng/ml). GABA (100 mg/ml) and TRH 100 ng/ml) on PRL release in vitro suggested little or no involvement of these putative regulatory factors in PRL cell regulation.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000818:Animals; D004294:Domperidone / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology / Q000502:physiology*; D010134:Fenclonine / Q000494:pharmacology; D007980:Levodopa / Q000494:pharmacology; D010902:Pituitary Gland / Q000166:cytology / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D012487:Salmonidae / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D013004:Somatostatin / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology; D014337:Trout / Q000502:physiology*; D014364:Tryptophan / Q000494:pharmacology
D012701:Serotonin; D007980:Levodopa; D013004:Somatostatin; D004294:Domperidone; D013973:Thyrotropin-Releasing Hormone; D014364:Tryptophan; D011388:Prolactin; D006916:5-Hydroxytryptophan; D010134:Fenclonine; D004298:Dopamine